atc_level_01_code,atc_level_01_name,atc_level_02_code,atc_level_02_name,atc_level_03_code,atc_level_03_name,atc_level_04_code,atc_level_04_name,atc_level_04_note,atc_level_05_code,atc_level_05_name,atc_level_05_note,DDD_inhalesolution,DDD_N,DDD_O,DDD_P,unit_inhalesolution,unit_N,unit_O,unit_P
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA01,dicoumarol,NA,NA,NA,0.1,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA02,phenindione,NA,NA,NA,0.1,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA03,warfarin,NA,NA,NA,7.5,7.5,NA,NA,mg,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA04,phenprocoumon,NA,NA,NA,3,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA07,acenocoumarol,NA,NA,NA,5,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA08,ethyl biscoumacetate,NA,NA,NA,0.6,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA09,clorindione,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA10,diphenadione,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA11,tioclomarol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AA,Vitamin K antagonists,The DDDs are based on prophylaxis of thrombosis.,B01AA12,fluindione,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB01,heparin,NA,NA,NA,NA,10,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB02,antithrombin III,NA,NA,NA,NA,2.1,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB04,dalteparin,anti Xa,NA,NA,NA,2.5,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB05,enoxaparin,anti Xa,NA,NA,NA,2,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB06,nadroparin,anti Xa,NA,NA,NA,2.85,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB07,parnaparin,anti Xa,NA,NA,NA,3.2,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB08,reviparin,anti Xa,NA,NA,NA,1.43,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB09,danaparoid,anti Xa,NA,NA,NA,1.5,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB10,tinzaparin,anti Xa,NA,NA,NA,3.5,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB11,sulodexide,LSU = lipoprotein lipase releasing units,NA,NA,500,500,NA,NA,LSU,LSU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB12,bemiparin,NA,NA,NA,NA,2.5,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AB,Heparin group,"The DDDs of nonfractionated heparin and antithrombin are based on prophylaxis of thrombosis and pulmonary emboli, and given in international units (U).  The DDDs for the different low molecular weight heparins are assigned according to their recommended dose in prophylaxis of deep vein thrombosis in moderate risk patients.  Since the anti Xa activity is a major determinant of the anticoagulant activity of low molecular weight heparins the DDDs are given in international units based on anti Xa activity.The DDD for sulodexide is expressed in lipoprotein lipase releasing units (LSU).",B01AB51,"heparin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC01,ditazole,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC02,cloricromen,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC03,picotamide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC04,clopidogrel,NA,NA,NA,75,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC05,ticlopidine,NA,NA,NA,0.5,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC06,acetylsalicylic acid,Independent of strength,NA,NA,1,NA,NA,NA,tablet,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC07,dipyridamole,NA,NA,NA,0.4,0.2,NA,NA,g,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC08,carbasalate calcium,NA,NA,NA,1,NA,NA,NA,tablet,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC09,epoprostenol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC10,indobufen,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC11,iloprost,NA,0.15,NA,NA,50,mg,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC13,abciximab,NA,NA,NA,NA,25,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC15,aloxiprin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC16,eptifibatide,NA,NA,NA,NA,0.2,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC17,tirofiban,NA,NA,NA,NA,10,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC18,triflusal,NA,NA,NA,0.6,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC19,beraprost,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC21,treprostinil,NA,NA,NA,NA,4.3,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC22,prasugrel,NA,NA,NA,10,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC23,cilostazol,NA,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC24,ticagrelor,NA,NA,NA,0.18,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC25,cangrelor,NA,NA,NA,NA,50,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC26,vorapaxar,NA,NA,NA,2.08,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC27,selexipag,NA,NA,NA,1.8,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC28,limaprost,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AC,Platelet aggregation inhibitors excl. heparin,"The DDDs are based on prophylaxis of thrombosis.  The DDDs of acetylsalicylic acid and carbasalate calcium are given as 1 tablet independent of tablet strength.  This is due to the great variations between different countries in the dosages/strengths recommended for prophylaxis of thrombosis.The DDD of iloprost is based on treatment of peripheral vascular disease.The DDD of vorapaxar is based on the content of one tablet (2.08 mg).The DDD of selexipag is based on treatment of pulmonary arterial hypertension.For combinations products, see list of DDDs for combinations, www.whocc.no.",B01AC56,"acetylsalicylic acid, combinations with proton pump inhibitors",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD01,streptokinase,NA,NA,NA,NA,1.5,NA,NA,NA,MU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD02,alteplase,NA,NA,NA,NA,0.1,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD03,anistreplase,NA,NA,NA,NA,30,NA,NA,NA,U
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD04,urokinase,NA,NA,NA,NA,3,NA,NA,NA,MU
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD05,fibrinolysin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD06,brinase,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD07,reteplase,NA,NA,NA,NA,20,NA,NA,NA,U
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD08,saruplase,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD09,ancrod,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD10,drotrecogin alfa (activated),NA,NA,NA,NA,40,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD11,tenecteplase,NA,NA,NA,NA,40,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD12,protein C,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AD,Enzymes,"The DDDs of streptokinase, alteplase, anistreplase and reteplase are based on thrombolytic treatment in connection with acute myocardial infarction.  The DDD of urokinase is based on treatment of acute lung emboli.  The DDDs are either expressed in international units or gram.",B01AD13,apadamtase alfa and cinaxadamtase alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE01,desirudin,NA,NA,NA,NA,30,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE02,lepirudin,NA,NA,NA,NA,0.25,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE03,argatroban,NA,NA,NA,NA,0.2,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE04,melagatran,NA,NA,NA,NA,6,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE05,ximelagatran,NA,NA,NA,48,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE06,bivalirudin,NA,NA,NA,NA,0.25,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AE,Direct thrombin inhibitors,The DDD for dabigatran etexilate is based on  treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AE07,dabigatran etexilate,NA,NA,NA,0.3,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF01,rivaroxaban,NA,NA,NA,20,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF02,apixaban,NA,NA,NA,10,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF03,edoxaban,NA,NA,NA,60,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF04,betrixaban,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AF,Direct factor Xa inhibitors,The DDDs are based on the treatment of patients with NVAF (nonvalvular atrial fibrillation).,B01AF51,rivaroxaban and acetylsalicylic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX01,defibrotide,NA,NA,NA,NA,1.75,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX04,dermatan sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX05,fondaparinux,NA,NA,NA,NA,2.5,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B01,ANTITHROMBOTIC AGENTS,B01A,ANTITHROMBOTIC AGENTS,B01AX,Other antithrombotic agents,The DDD for caplacizumab is 10 mg (P) based on the European labelling and equivalent to 11 mg in the USA labelling.,B01AX07,caplacizumab,NA,NA,NA,NA,10,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA01,aminocaproic acid,NA,NA,NA,16,16,NA,NA,g,g
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA02,tranexamic acid,NA,NA,NA,2,2,NA,NA,g,g
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AA,Amino acids,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AA03,aminomethylbenzoic acid,NA,NA,NA,0.25,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB01,aprotinin,NA,NA,NA,NA,500,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB02,alfa1 antitrypsin,NA,NA,NA,NA,0.6,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB04,camostat,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02A,ANTIFIBRINOLYTICS,B02AB,Proteinase inhibitors,The DDDs are based on treatment of hemorrhage associated with fibrinolysis.,B02AB05,ulinastatin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BA,Vitamin K,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BA01,phytomenadione,NA,NA,NA,20,20,NA,NA,mg,mg
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BA,Vitamin K,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BA02,menadione,NA,NA,NA,10,2,NA,NA,mg,mg
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BB,Fibrinogen,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.).",B02BB01,"fibrinogen, human",NA,NA,NA,NA,5,NA,NA,NA,g
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC01,absorbable gelatin sponge,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC02,oxidized cellulose,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC03,tetragalacturonic acid hydroxymethylester,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC05,adrenalone,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC06,thrombin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC07,collagen,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC08,calcium alginate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC09,epinephrine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BC,Local hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for local hemostatics classified in this group.",B02BC30,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD01,"coagulation factor IX, II, VII and X in combination",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD02,coagulation factor VIII,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD03,factor VIII inhibitor bypassing activity,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD04,coagulation factor IX,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD05,coagulation factor VII,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD06,von Willebrand factor and coagulation factor VIII in combination,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD07,coagulation factor XIII,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD08,coagulation factor VIIa,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD10,von Willebrand factor,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD11,catridecacog,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD13,coagulation factor X,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD14,susoctocog alfa,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD15,valoctocogene roxaparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD16,etranacogene dezaparvovec,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BD,Blood coagulation factors,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). No DDDs are established for blood coagulation factors. The use of blood coagulation factors could be measured in blood factor units (IU).",B02BD30,thrombin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX01,etamsylate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX02,carbazochrome,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX03,batroxobin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX04,romiplostim,NA,NA,NA,NA,30,NA,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX05,eltrombopag,NA,NA,NA,50,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX06,emicizumab,NA,NA,NA,NA,15,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX07,lusutrombopag,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX08,avatrombopag,NA,NA,NA,20,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX09,fostamatinib,NA,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B02,ANTIHEMORRHAGICS,B02B,VITAMIN K AND OTHER HEMOSTATICS,B02BX,Other systemic hemostatics,"The DDDs are based on treatment of hemorrhage associated with different deficiency states (e.g. vitamin K deficiency, deficiency of different blood coagulation factors etc.). The DDD for avatrombopag is based on the starting dose in the treatment of chronic immune thrombocytopenia.",B02BX10,concizumab,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA01,ferrous glycine sulfate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA02,ferrous fumarate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA03,ferrous gluconate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA04,ferrous carbonate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA05,ferrous chloride,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA06,ferrous succinate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA07,ferrous sulfate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA08,ferrous tartrate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA09,ferrous aspartate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA10,ferrous ascorbate,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA11,ferrous iodine,Fe2+,NA,NA,0.2,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AA,"Iron bivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  The DDDs are established according to amount of Fe2+ and are equal for all compounds regardless of iron salt (i.e. the DDD corresponds to 0.2 g Fe2+).,B03AA12,ferrous sodium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB01,ferric sodium citrate,Fe3+,NA,NA,0.75,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB02,saccharated iron oxide,Fe3+,NA,NA,0.11,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB03,sodium feredetate,Fe3+,NA,NA,0.17,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB04,ferric hydroxide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB05,ferric oxide polymaltose complexes,Fe3+,NA,NA,90,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB07,chondroitin sulfate-iron complex,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB08,ferric acetyl transferrin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB09,ferric proteinsuccinylate,Fe3+,NA,NA,80,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AB,"Iron trivalent, oral preparations",The DDDs are based on treatment of iron deficiency anemia.  Separate DDDs are established for the different trivalent iron salts. The DDDs are expressed in grams of Fe3+.,B03AB10,ferric maltol,Fe3+,NA,NA,60,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AC,"Iron, parenteral preparations",NA,B03AC,"Iron, parenteral preparations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD01,ferrous amino acid complex and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD02,ferrous fumarate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD03,ferrous sulfate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD04,ferric oxide polymaltose complexes and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AD,Iron in combination with folic acid,Historically:The DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy (i.e. about half the iron dose for treatment of anemia).,B03AD05,ferrous gluconate and folic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE01,"iron, vitamin B12 and folic acid",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE02,"iron, multivitamins and folic acid",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE03,iron and multivitamins,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE04,"iron, multivitamins and minerals",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03A,IRON PREPARATIONS,B03AE,Iron in other combinations,"Historically:For combinations of iron, vitamin B12 and folic acid (B03AE01), the DDDs have been based on prophylaxis of iron deficiency anemia and folic acid deficiency during pregnancy.Various combinations, classified in B03AE10, contain very small amounts of iron.  The DDDs for these combinations have been based on dose recommendations, and can be as low as corresponding to 30 mg Fe2+.The DDDs for iron in other combinations have been based on treatment of iron deficiency anemia, and correspond to a DDD of 0.2 g Fe2+.",B03AE10,various combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA01,cyanocobalamin,NA,NA,70,1,20,NA,mcg,mg,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA02,cyanocobalamin tannin complex,NA,NA,NA,NA,20,NA,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA03,hydroxocobalamin,NA,NA,NA,NA,20,NA,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA04,cobamamide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA05,mecobalamin,NA,NA,NA,1.5,0.2,NA,NA,mg,mg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA51,"cyanocobalamin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BA,Vitamin B12 (cyanocobalamin and analogues),The DDDs are based on maintenance treatment of pernicious anemia.  Different DDDs are assigned for oral and parenteral formulations of cyanocobalamin due to great differences in bioavailability.The DDD for mecobalamin is based on the treatment of peripheral neuropathies.,B03BA53,"hydroxocobalamin, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB01,folic acid,prophylactic dose,NA,NA,0.4,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB01,folic acid,therapeutic dose,NA,NA,NA,10,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03B,VITAMIN B12 AND FOLIC ACID,B03BB,Folic acid and derivatives,The DDD for oral folic acid is based on prophylactic use and the parenteral DDD is based on treatment.,B03BB51,"folic acid, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA01,erythropoietin,NA,NA,NA,NA,1,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA02,darbepoetin alfa,NA,NA,NA,NA,4.5,NA,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA03,methoxy polyethylene glycol-epoetin beta,NA,NA,NA,NA,4,NA,NA,NA,mcg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA04,peginesatide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA05,roxadustat,NA,NA,NA,43,NA,NA,NA,mg,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA06,luspatercept,NA,NA,NA,NA,3.33,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA07,daprodustat,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B03,ANTIANEMIC PREPARATIONS,B03X,OTHER ANTIANEMIC PREPARATIONS,B03XA,Other antianemic preparations,The DDDs are based on the treatment of renal anemia in patients maintained by dialysis.The DDD for luspatercept is based on the starting dose in the treatment of myelodydplastic syndromes and beta-thalassaemia.,B03XA08,vadadustat,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA01,albumin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA02,other plasma protein fractions,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA03,fluorocarbon blood substitutes,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA05,dextran,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA06,gelatin agents,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA07,hydroxyethylstarch,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA08,hemoglobin crosfumaril,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA09,hemoglobin raffimer,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AA,Blood substitutes and plasma protein fractions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AA10,hemoglobin glutamer (bovine),NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX01,erythrocytes,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX02,thrombocytes,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX03,blood plasma,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05A,BLOOD AND RELATED PRODUCTS,B05AX,Other blood products,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05AX04,stem cells from umbilical cord blood,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA01,amino acids,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA02,fat emulsions,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA03,carbohydrates,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA04,protein hydrolysates,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BA,Solutions for parenteral nutrition,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB01,electrolytes,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB02,electrolytes with carbohydrates,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB03,trometamol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BB,Solutions affecting the electrolyte balance,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BB04,electrolytes in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BC,Solutions producing osmotic diuresis,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BC01,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05B,I.V. SOLUTIONS,B05BC,Solutions producing osmotic diuresis,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05BC02,carbamide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA01,cetylpyridinium,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA02,chlorhexidine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA03,nitrofural,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA04,sulfamethizole,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA05,taurolidine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA06,mandelic acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA07,noxytiolin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA08,ethacridine lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA09,neomycin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CA,Antiinfectives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CA10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB01,sodium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB02,sodium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB03,magnesium citrate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB04,sodium bicarbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CB,Salt solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CB10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX01,glucose,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX02,sorbitol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX03,glycine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX04,mannitol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05C,IRRIGATING SOLUTIONS,B05CX,Other irrigating solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05CX10,combinations,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05D,PERITONEAL DIALYTICS,B05DA,Isotonic solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05D,PERITONEAL DIALYTICS,B05DB,Hypertonic solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA01,potassium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA02,sodium bicarbonate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA03,sodium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA04,ammonium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA05,magnesium sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA06,"potassium phosphate, incl. combinations with other potassium salts",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA07,calcium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA08,sodium acetate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA09,sodium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA10,magnesium phosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA11,magnesium chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA12,zinc chloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA13,hydrochloric acid,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA14,sodium glycerophosphate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA15,potassium lactate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA16,cardioplegia solutions,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA17,potassium acetate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA18,zinc sulfate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA19,calcium gluconate,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA20,sodium selenite,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA30,combinations of electrolytes,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XA,Electrolyte solutions,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XA31,electrolytes in combination with other drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB01,arginine hydrochloride,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB02,alanyl glutamine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XB,Amino acids,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XB03,lysine,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XC,Vitamins,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05X,I.V. SOLUTION ADDITIVES,B05XX,Other i.v. solution additives,"No DDDs are established in this group.  It is considered difficult to establish DDDs, because of the great variations in dosages given.",B05XX02,trometamol,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05Z,HEMODIALYTICS AND HEMOFILTRATES,B05ZA,"Hemodialytics, concentrates",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B05,BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS,B05Z,HEMODIALYTICS AND HEMOFILTRATES,B05ZB,Hemofiltrates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA02,fibrinolysin and desoxyribonuclease,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA03,hyaluronidase,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA04,chymotrypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA07,trypsin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA10,desoxyribonuclease,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AA,Enzymes,NA,B06AA55,"streptokinase, combinations",NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AB,Heme products,NA,B06AB01,hemin,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC01,"c1-inhibitor, plasma derived",NA,NA,NA,NA,1.4,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC02,icatibant,NA,NA,NA,NA,30,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC03,ecallantide,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC04,conestat alfa,NA,NA,NA,NA,3.5,NA,NA,NA,TU
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC05,lanadelumab,NA,NA,NA,NA,21.4,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AC,Drugs used in hereditary angioedema,The DDD for lanadelumab is based on the starting dose.,B06AC06,berotralstat,NA,NA,NA,0.15,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX01,crizanlizumab,NA,NA,NA,NA,12.5,NA,NA,NA,mg
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX02,betibeglogene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX03,voxelotor,NA,NA,NA,NA,NA,NA,NA,NA,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX04,mitapivat,NA,NA,NA,0.1,NA,NA,NA,g,NA
B,BLOOD AND BLOOD FORMING ORGANS,B06,OTHER HEMATOLOGICAL AGENTS,B06A,OTHER HEMATOLOGICAL AGENTS,B06AX,Other hematological agents,NA,B06AX05,exagamglogene autotemcel,NA,NA,NA,NA,NA,NA,NA,NA,NA
